Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.48 |
| ▸ | GRM5 | P41594 | 10/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31083549 | 1.00 | GRM1 (0.48) | GRM1GRM5TNK2PDK4CNR1 | |
| SCHEMBL18081229 | 0.84 | PDK4 (0.51) | GRM1GRM5TNK2PDK4CNR1 | |
| SCHEMBL29910537 | 0.84 | PDK4 (0.51) | GRM1GRM5TNK2PDK4CNR1 | |
| SCHEMBL74150 | 0.83 | TNK2 (0.49) | GRM1GRM5TNK2PDK4CNR1 | |
| SCHEMBL31083662 | 0.82 | GRM1 (0.49) | GRM1GRM5TNK2PDK4CNR1 | |
| SCHEMBL25309653 | 0.82 | GRM1 (0.49) | GRM1GRM5TNK2PDK4CNR1 | |
| SCHEMBL31083663 | 0.82 | NR1H2 (0.41) | CNR1 | |
| SCHEMBL25309022 | 0.82 | NR1H2 (0.41) | CNR1 | |
| SCHEMBL31548749 | 0.81 | BTK (0.49) | GRM1GRM5TNK2PDK4CNR1 | |
| SCHEMBL21045788 | 0.81 | GRM1 (0.52) | GRM1GRM5TNK2PDK4JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100997-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-03-27 | — | — | US | disclosed |
| EP-4463448-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-11-20 | — | — | EP | disclosed |
| CN-118541362-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2023135107-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023135107-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100997-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | GRM1 1230/4885GRM5 104/4885TNK2 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.